Meningitis Differential Diagnoses
- Author: Raymund R Razonable, MD; Chief Editor: Burke A Cunha, MD more...
Diagnostic Considerations
Diagnoses to consider aside from meningitis include the following:
- Noninfectious meningitis, including medication-induced meningeal inflammation
- Meningeal carcinomatosis
- CNS vasculitis
- Stroke
- Encephalitis
- All causes of altered mental status and coma
- Leptospirosis
- Subdural empyema
Differential Diagnoses
- Brain Abscess
- Delirium Tremens
- Encephalitis
- Herpes Simplex
- Herpes Simplex Encephalitis
- Neoplasms, Brain
- Pediatrics, Febrile Seizures
- Pediatrics, Meningitis and Encephalitis
- Subarachnoid Hemorrhage
Mann K, Jackson MA. Meningitis. Pediatr Rev. Dec 2008;29(12):417-29; quiz 430. [Medline].
Ginsberg L, Kidd D. Chronic and recurrent meningitis. Pract Neurol. Dec 2008;8(6):348-61. [Medline].
Berkhout B. Infectious diseases of the nervous system: pathogenesis and worldwide impact. IDrugs. Nov 2008;11(11):791-5. [Medline].
Nkoumou MO, Clevenbergh P, Betha G, Kombila M. Bacterial meningitis in HIV positive compared to HIV negative patients in an internal medicine ward of Librevile, Gabon. . Int Conf AIDS: International Conference on AIDS. Jul 7-12 2002;abstract no. ThPeB7368.
Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis. Dec 1 2002;186 Suppl 2:S225-33. [Medline].
Thigpen, M, Rosenstein, NE, Whitney, CG. Bacterial meningitis in the United States --1998-2003. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA. October 2005;65.
Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. May 26 2011;364(21):2016-25. [Medline].
van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med. Jan 5 2006;354(1):44-53. [Medline].
Moses S. Meningitis: acute bacterial meningitis. Accessed February 8, 2011. Available at http://www.fpnotebook.com/neuro/ID/Mngts.htm.
Worsoe L, Caye-Thomasen P, Brandt CT, Thomsen J, Ostergaard C. Factors associated with the occurrence of hearing loss after pneumococcal meningitis. Clin Infect Dis. Oct 15 2010;51(8):917-24. [Medline].
[Best Evidence] Dubos F, Korczowski B, Aygun DA, Martinot A, Prat C, Galetto-Lacour A, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med. Dec 2008;162(12):1157-63. [Medline].
Gilbert DN, Moellering RC Jr, Sande MA. Antimicrobial Therapy. In: Sanford Guide to Antimicrobial Therapy. 33rd ed. March 15, 2003.
van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis. Mar 2004;4(3):139-43. [Medline].
van de Beek D, de Gans J. Dexamethasone and pneumococcal meningitis. Ann Intern Med. Aug 17 2004;141(4):327. [Medline].
Peltola H, Roine I. Improving the outcomes in children with bacterial meningitis. Curr Opin Infect Dis. Jun 2009;22(3):250-5. [Medline].
[Best Evidence] Sloan D, Dlamini S, Paul N, Dedicoat M. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev. Oct 8 2008;CD005647. [Medline].
Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep. May 2 2008;57(17):462-5. [Medline].
[Guideline] Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. Jan 28 2011;60(3):72-6. [Medline]. [Full Text].
Seupaul RA. Evidence-based emergency medicine/rational clinical examination abstract. How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis?. Ann Emerg Med. Jul 2007;50(1):85-7. [Medline].
- Table 1. Infectious Agents Causing Aseptic Meningitis Syndrome
- Table 2. Causes of Chronic Meningitis
- Table 3. Changing Epidemiology of Acute Bacterial Meningitis in the United States*
- Table 4. The Most Common Bacterial Pathogens Based on Age and Predisposing Risks
- Table 5. CSF Picture of Meningitis According to Etiologic Agent
- Table 6. Comparison of CSF Findings by Type of Organism
- Table 7. Recommended Empiric Antibiotics According to Predisposing Factors for Patients With Suspected Bacterial Meningitis
- Table 8. Recommended Empiric Antibiotics for Patients With Suspected Bacterial Meningitis and Known CSF Gram Stain Results
- Table 9. Specific Antibiotics and Duration of Therapy for Patients With Acute Bacterial Meningitis
| Category | Agent |
| Bacteria | Partially-treated bacterial meningitis L monocytogenes Brucella species Rickettsia rickettsii Ehrlichia species Mycoplasma pneumoniae Borrelia burgdorferi Treponema pallidum Leptospira species Mycobacterium tuberculosis Nocardia species |
| Parasites | N fowleri Acanthamoeba species Balamuthia species Angiostrongylus cantonensis G spinigerum Baylisascaris procyonis S stercoralis Taenia solium (cysticercosis) |
| Fungi | Cryptococcus neoformans C immitis Blastomyces dermatitidis H capsulatum Candida species Aspergillus species |
| Viruses | Enterovirus Poliovirus Echovirus Coxsackievirus A Coxsackievirus B Enterovirus 68-71 |
| Herpesvirus HSV-1 and HSV-2 Varicella-zoster virus EBV CMV HHV*-6 HHV-7 | |
| Paramyxovirus Mumps virus Measles virus | |
| Togavirus Rubella virus | |
| Flavivirus Japanese encephalitis virus St. Louis encephalitis virus | |
| Bunyavirus California encephalitis virus La Crosse encephalitis virus | |
| Alphavirus Eastern equine encephalitis virus Western equine encephalitis virus Venezuelan encephalitis virus | |
| Reovirus Colorado tick fever virus | |
| Arenavirus LCM virus** | |
| Rhabdovirus Rabies virus | |
| Retrovirus HIV*** | |
| *Human herpes virus **Lymphocytic choriomeningitis ***Human immunodeficiency virus | |
| Category | Agent |
| Bacteria | M tuberculosis B burgdorferi T pallidum Brucella species Francisella tularensis Nocardia species Actinomyces species |
| Fungi | C neoformans C immitis B dermatitidis H capsulatum Candida albicans Aspergillus species Sporothrix schenckii |
| Parasites | Acanthamoeba species N fowleri Angiostrongylus cantonensis G spinigerum B procyonis Schistosoma species S stercoralis Echinococcus granulosus |
| Bacteria | 1978-1981 | 1986 | 1995 | 1998-2007 | |
| H influenzae | 48% | 45% | 7% | 6.7% | |
| Listeria monocytogenes | 2% | 3% | 8% | 3.4% | |
| N meningitidis | 20% | 14% | 25% | 13.9% | |
| S agalactiae | 3% | 6% | 12% | 18.1% | |
| S pneumoniae | 13% | 18% | 47% | 58% | |
| *Nosocomial meningitis is not included. These data include only the 5 major meningeal pathogens. | |||||
| Risk and/or Predisposing Factor | Bacterial Pathogen |
| Age 0-4 weeks | Streptococcus agalactiae (group B streptococci) E coli K1 Listeria monocytogenes |
| Age 4-12 weeks | S agalactiae E coli H influenzae S pneumoniae N meningitidis |
| Age 3 months to 18 years | N meningitidis S pneumoniae H influenzae |
| Age 18-50 years | S pneumoniae N meningitidis H influenzae |
| Age older than 50 years | S pneumoniae N meningitidis L monocytogenes Aerobic gram-negative bacilli |
| Immunocompromised state | S pneumoniae N meningitidis L monocytogenes Aerobic gram-negative bacilli |
| Intracranial manipulation, including neurosurgery | Staphylococcus aureus Coagulase-negative staphylococci Aerobic gram-negative bacilli, including P aeruginosa |
| Basilar skull fracture | S pneumoniae H influenzae Group A streptococci |
| CSF shunts | Coagulase-negative staphylococci S aureus Aerobic gram-negative bacilli Propionibacterium acnes |
| Agent | Opening Pressure | WBC count per µL | Glucose (mg/dL) | Protein (mg/dL) | Microbiology |
| Bacterial meningitis | 200-300 | 100-5000; >80% PMNs* | < 40 | >100 | Specific pathogen demonstrated in 60% of Gram stains and 80% of cultures |
| Viral meningitis | 90-200 | 10-300; lymphocytes | Normal, reduced in LCM and mumps | Normal but may be slightly elevated | Viral isolation, PCR† assays |
| Tuberculous meningitis | 180-300 | 100-500; lymphocytes | Reduced, < 40 | Elevated, >100 | Acid-fast bacillus stain, culture, PCR |
| Cryptococcal meningitis | 180-300 | 10-200; lymphocytes | Reduced | 50-200 | India ink, cryptococcal antigen, culture |
| Aseptic meningitis | 90-200 | 10-300; lymphocytes | Normal | Normal but may be slightly elevated | Negative findings on workup |
| Normal values | 80-200 | 0-5; lymphocytes | 50-75 | 15-40 | Negative findings on workup |
| *Polymorphonuclear lymphocytes †Polymerase chain reaction | |||||
| Bacterial Meningitis | Viral Meningitis* | Fungal Meningitis** | |
| Pressure 5-15 cm H2 O | Increased | Normal or mildly increased | Normal or mildly increased in TB. May be increased in fungal. AIDS patients with cryptococcal meningitis have increased risk of blindness, death unless maintained at < 30 cm. |
| Cell count preterm: 0-25 term: 0-22 >6 months: 0-5 mononuclear cells/mm3 | No cell count result can exclude bacterial meningitis. Typically thousands of PMNs, but may be less dramatic or even normal (classically, in very early meningococcal meningitis and in extremely ill neonates). Lymphocytosis with normal CSF chemistries seen in 15-25%, especially when cell counts < 1000 or if partially treated. Approximately 90% of patients with ventriculoperitoneal shunts have CSF WBC count >100 cells/mm3 are infected; CSF glucose usually normal, and organisms are less pathogenic. Cell count and chemistries normalize slowly (over days) with antibiotics. | Usually < 500 cells, nearly 100% mononuclear. Up to 48 hours, significant PMN pleocytosis may be indistinguishable from early bacterial meningitis; this is particularly true with eastern equine encephalitis. Presence of nontraumatic RBCs in 80% of HSV meningoencephalitis, although 10% have normal CSF results | Hundreds of mononuclear cells |
| Micro no organisms | Gram stain 80% sensitive. Inadequate decolorization may mistake H influenzae for gram-positive cocci. Pretreatment with antibiotics may affect stain uptake, causing gram-positive organisms to appear gram negative and decrease culture yield on average 20%. | No organism | India ink 80-90% sensitive for fungi; AFB stain 40% sensitive for TB (increase yield by staining supernate from at least 5 cc CSF) |
| Glucose euglycemia: >50% serum hyperglycemia: >30% serum wait 4 h after glucose load | Decreased | Normal | Sometimes decreased. Aside from fulminant bacterial meningitis, the lowest levels of CSF glucose are seen in TB, primary amebic meningoencephalitis, neurocysticercosis |
| Protein preterm: 65-150 term: 20-170 >6 months: 15-45 mg/dL | Usually >150, may be >1000 | Mildly increased | Increased; >1000 with relatively benign clinical presentation suggestive of fungal disease |
| *Some bacteria (eg, Mycoplasma, Listeria, Leptospira species, Borrelia burgdorferi [Lyme], spirochetes) produce spinal fluid alterations that resemble the viral profile. An aseptic profile also is typical of partially treated bacterial infections (more than 33% of patients have received antimicrobial treatment, especially children) and the 2 most common causes of encephalitis — the potentially curable HSV and arboviruses. **In contrast, tuberculous meningitis and parasites resemble the fungal profile more closely. | |||
| Predisposing Feature | Antibiotic(s) |
| Age 0-4 weeks | Ampicillin plus cefotaxime or an aminoglycoside |
| Age 1-3 months | Ampicillin plus cefotaxime plus vancomycin* |
| Age 3 months to 50 years | Ceftriaxone or cefotaxime plus vancomycin* |
| Older than 50 years | Ampicillin plus ceftriaxone or cefotaxime plus vancomycin* |
| Impaired cellular immunity | Ampicillin plus ceftazidime plus vancomycin* |
| Neurosurgery, head trauma, or CSF shunt | Vancomycin plus ceftazidime |
| *Vancomycin is added empirically to the initial regimen if the presence of penicillin-resistant S pneumoniae is suspected or if a high incidence of resistance is reported in the community. | |
| Gram Stain Morphology | Antibiotic(s) |
| Gram-positive cocci | Vancomycin plus ceftriaxone or cefotaxime |
| Gram-negative cocci | Penicillin G* |
| Gram-positive bacilli | Ampicillin plus an aminoglycoside |
| Gram-negative bacilli | Broad-spectrum cephalosporin† plus an aminoglycoside |
| *Use ceftriaxone if penicillin-resistant N meningitidis occurs in the community. †Ceftriaxone is preferred. Ceftazidime is used when Pseudomonas infection is likely (eg, neurosurgical procedures). | |
| Bacteria | Susceptibility | Antibiotic(s) | Duration (Days) |
| S pneumoniae | Penicillin MIC < 0.1 mg/L | Penicillin G | 10-14 |
| MIC 0.1-1 mg/L | Ceftriaxone or cefotaxime | ||
| MIC >2 mg/L | Ceftriaxone or cefotaxime | ||
| Ceftriaxone MIC >0.5 mg/L | Ceftriaxone or cefotaxime plus vancomycin or rifampin | ||
| H influenzae | Beta-lactamase-negative | Ampicillin | 7 |
| Beta-lactamase-positive | Ceftriaxone or cefotaxime | ||
| N meningitidis | ... | Penicillin G or ampicillin | 7 |
| L monocytogenes | ... | Ampicillin or penicillin G plus an aminoglycoside | 14-21 |
| S agalactiae | ... | Penicillin G plus an aminoglycoside, if warranted | 14-21 |
| Enterobacteriaceae | ... | Ceftriaxone or cefotaxime plus an aminoglycoside | 21 |
| P aeruginosa | ... | Ceftazidime plus an aminoglycoside | 21 |

